Stress Testing and Cardiac Magnetic Resonance

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 4, 2014

Study Completion Date

June 4, 2014

Conditions
Coronary Disease
Interventions
DRUG

regadenoson

Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of Chicago

OTHER

NCT00871260 - Stress Testing and Cardiac Magnetic Resonance | Biotech Hunter | Biotech Hunter